Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
ASCO Immunotherapy Roundup - 4: Merck KGaA Trailing Rivals with ADCC-Inducing Avelumab
Merck KGaA’s tie-up with Pfizer on the investigational anti-PD-L1 antibody avelumab made headlines last year. In the fourth of this series, we sat down with the Japan R&D head of Merck Serono, the pharmaceutical unit of Merck KGaA, to talk…
To read the full story
Related Article
- ASCO Immunotherapy Roundup - 9: Researcher Says Predominance of Anti-PD-1 Antibodies Not Assured
September 1, 2015
- ASCO Immunotherapy Roundup - 8: 5 Immune Checkpoint Inhibitors Projected to Rake in 2 Trillion Yen in 2020
August 25, 2015
- ASCO Immunotherapy Roundup - 7: Patient Group Hails Dawn of New Cancer Treatment Era
August 14, 2015
- ASCO Immunotherapy Roundup - 6: CAR T-Cell Therapy Another Hot Field in Immuno-Oncology
August 12, 2015
- ASCO Immunotherapy Roundup - 5: Merck & Co. Discovers New Biomarkers for Keytruda
August 7, 2015
- ASCO Immunotherapy Roundup - 3: AZ Set to Harness Rich Pipeline to Pursue Combo Strategy
July 16, 2015
- ASCO Immunotherapy Roundup - 2: Chugai Has High Hopes for Atezolizumab Combos with Group Portfolios
July 14, 2015
- ASCO Immunotherapy Roundup - 1: Opdivo Data Boost Confidence in BMS’s Combination Strategy
July 7, 2015
BUSINESS
- G1 Reform Will Accelerate LLP Transfers, Fuel Competition: LTL Chief
April 15, 2026
- Daiichi Sankyo’s I-DXd Filed in US for SCLC, Wins Priority Review
April 15, 2026
- Nxera’s Partner Earns Taiwan Approval for Daridorexant
April 15, 2026
- Sanofi Japan Sales Rise 4.5% in 2025 as Dupixent Widens Label
April 15, 2026
- Eylea Biosimilar Supply Curbed amid Originator Disruption
April 14, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…